Carol Peña
Seminars
Wednesday 7th October 2026
Panel Discussion: Transforming Patient Monitoring Through Innovation in Liquid Biopsy Analytes, Detection Sensitivity & Data Interpretation
12:50 pm
- What are the most impactful recent innovations in liquid biopsy biomarkers, and how can these be robustly validated and effectively integrated into clinical trial designs?
- How can drug-diagnostic stakeholders build high-value, collaborative frameworks to advance liquid biopsy technologies, particularly in improving detection sensitivity, standardization, and data interpretation?
Tuesday 6th October 2026
Integrating Science & Strategy to Advance Companion Diagnostic Development for Optimal Patient Treatment
2:30 pm
- Discussing how CDx offer the ability to select optimal treatments for each patient based on biology, while the field continues to expand rapidly amid technological and regulatory change
- CDx development must balance optimal test performance, ideal technologies, and innovative approaches with global accessibility, testing paradigm fit, development and test cost, while fulfilling regulatory requirements
- Showcasing how technologies such as digital pathology with AI and ML-based interpretation, ctDNA, and multiplex assays offer the potential for increased accuracy in supporting optimal treatment selection for each patient, but each presents its own challenges
